Priority Healthcare Added To NASDAQ Biotechnology Index

Priority Healthcare Added To NASDAQ Biotechnology Index 


LAKE MARY, Fla., Nov. 14  /PRNewswire-FirstCall/ -- Priority Healthcare
Corporation  will be added to the NASDAQ Biotechnology Index  effective Monday,
November 24, 2003.

"We are very pleased to join the NASDAQ Biotechnology Index, which is composed
of the largest and most actively traded NASDAQ biotechnology and pharmaceutical
companies as classified by FTSE.  This listing is a testament to Priority's
strength and reliability as a market leader in specialty pharmacy and
distribution.  Since 2000, the NASDAQ Biotechnology Index has outperformed the
NASDAQ Composite, the S&P 500, and the Dow Jones Industrial Average," said Steve
Cosler, President and Chief Executive Officer.  "Priority Healthcare's
commitment to serving patients, physicians, payors and pharmaceutical
manufacturers continues to be a driving factor in the growth of our company and
the solid returns we've earned for our investors."

The NASDAQ Biotechnology Index is designed to provide investors with a benchmark
of stock performance for biotechnology and pharmaceutical companies as defined
by the FTSE(TM) Global Classification System.  This includes companies where the
majority of revenue is derived from the sale, licensing, and/or distribution of
biopharmaceutical and pharmaceutical medications.  The NASDAQ Biotechnology
Index is calculated under a modified capitalization- weighted methodology.  For
more information on the NASDAQ Biotechnology Index, please visit
http://www.nasdaq.com/.

About Priority Healthcare Corporation

Priority Healthcare Corporation is a national specialty pharmacy and distributor
that provides biopharmaceuticals, complex therapies, and related disease
treatment programs and services.  Priority Healthcare provides comprehensive
programs for patients, payors, physicians, and pharmaceutical manufacturers for
a growing number of disease states including cancer, hepatitis C, respiratory
and pulmonary conditions, infertility, rheumatoid arthritis, hemophilia, and
multiple sclerosis.  Additional information regarding Priority Healthcare is
available at http://www.priorityhealthcare.com/

Certain statements included in this press release, which are not historical
facts, are forward-looking statements.  Such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.  These forward-looking statements represent our expectations
or beliefs and involve certain risks and uncertainties, including those
described in our public filings with the United States Securities and Exchange
Commission; also including, but not limited to, changes in interest rates,
competitive pressures, changes in customer mix, changes in third party
reimbursement rates, financial stability of major customers, changes in
government regulations or the interpretation of these regulations, changes in
supplier relationships, growth opportunities, cost savings, revenue
enhancements, synergies and other benefits anticipated from acquisition
transactions, difficulties relative to integrating acquired businesses, the
accounting and tax treatment of acquisitions, and asserted and unasserted
claims, which could cause actual results to differ from those in the
forward-looking statements.  The forward-looking statements by their nature
involve substantial risks and uncertainties, certain of which are beyond our
control, and actual results may differ materially depending on a variety of
important factors.  You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date herein. 

http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGO

http://photoarchive.ap.org/

DATASOURCE: Priority Healthcare Corporation



CONTACT:  Financial, Stephen Saft, Chief Financial Officer,

[phone], or Media, Kirsten Ayars, Public Relations Manager,

[phone], both of Priority Healthcare



Web site:  http://www.priorityhealthcare.com/

Copyright